Incyte vs Stripe
Side-by-side comparison of AI visibility scores, market position, and capabilities
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
Global payments infrastructure founded by Patrick and John Collison (YC W10); $1.4T payments volume in 2024; $18B+ revenue; $106.7B valuation as of Sept 2025; powers everything from startups to Fortune 500 companies with developer-first API design.
About
Stripe is a global payments infrastructure company founded in 2010 by Irish brothers Patrick and John Collison, headquartered in San Francisco, California and Dublin, Ireland. Stripe was born from the insight that accepting payments online was unnecessarily complex for developers, and that a well-designed API could unlock an entire generation of internet businesses. The company went through Y Combinator's Winter 2010 batch and grew to become the defining payments infrastructure layer of the modern internet economy, processing payments for businesses in virtually every industry worldwide.\n\nStripe's platform provides payment processing, fraud prevention via Stripe Radar, subscription billing, revenue recognition, banking-as-a-service through Stripe Treasury, corporate card issuance, identity verification, and tax compliance tools. It serves a spectrum from early-stage startups to publicly traded enterprises including Amazon, Google, Salesforce, and Shopify. Stripe's developer-first philosophy — comprehensive documentation, SDKs in every major language, and a sandbox testing environment — created an ecosystem of millions of businesses built entirely on its infrastructure.\n\nStripe processed $1.4 trillion in total payment volume in 2024 and generates over $18 billion in annual revenue, with a valuation of $106.7 billion as of September 2025. The company has remained private longer than most comparably sized technology companies, giving it flexibility to invest in long-term product expansion. An April 2024 partnership with Apple Pay extended Stripe's reach further into mobile and in-store commerce. Stripe competes with Adyen, Braintree (PayPal), and Square, but its developer ecosystem depth and global infrastructure make it the default payments platform for a generation of technology companies.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.